ToxStrategies scientists have published a manuscript in the journal Regulatory Toxicology and Pharmacology reporting the outcome of a state-of-the-science assessment to develop recommendations for oral consumer use of hemp-derived cannabidiol (CBD) isolate. Using a systematic approach to review the publicly available human and animal safety data on CBD, a potential acceptable daily intake (ADI) value was derived for the general population and from all sources, as were recommended upper intake limits (ULs) for dietary supplement use by healthy adults. It is anticipated that the recommended values from this study will be informative for risk assessors and regulators interested in characterizing human health hazards and determining recommendations for consumer intake of CBD. Led by Dr. Rayetta Henderson, ToxStrategies coauthors included Ms. Melissa Vincent, Dr. Brianna Rivera, and Dr. Candace Doepker.
Dr. Henderson has been involved in leading-edge research on the safety of hemp-derived products, and the study can be accessed here. Additional ToxStrategies services related to Cannabinoid and Industrial Hemp Safety can be found here.